Posts tagged mAb
Maxim starts Immune Pharma at buy; PT $3

Maxim Group launched coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $3 price target. The stock closed at 57 cents on Jan. 4.

Read More
Ladenburg starts Leap Therapeutics at buy

Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6.

Read More